Search clinical trials for: Nafamostat mesilate

Total 71 results

Xiaotong Hou

Not yet recruiting

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Extracorporeal Membrane Oxygenation Complication

China
Xu Li
LanZhou University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaborators

Not yet recruiting

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy (NMSICRCT)

Sepsis | Sepsis-induced Coagulopathy | Nafamostat Mesilate
First Affiliated Hospital Xi'an Jiaotong University
Second Affiliated Hospital of Xi'an Jiaotong University; Tang-Du Hospital; Shangluo... and other collaborators

Not yet recruiting

Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients (NMFADCICIP)

Hemorrhage | Trauma | AKI | Sepsis Syndrome | Thrombus | MODS

China
University of Edinburgh
University of Oxford; Latus Therapeutics; Scottish National Blood Transfusion...

Recruiting

DEFINE - Evaluating Therapies for COVID-19 (DEFINE)

COVID-19

United Kingdom
University Hospital Padova
University of Zurich; Yokohama City University

Recruiting

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)

COVID19

Italy
University of Melbourne
Australian and New Zealand Intensive Care Research Centre; The Peter Doherty... and other collaborators

Active, not recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT)

SARS-CoV-2 Infection (COVID-19)

Australia
Ensysce Biosciences
National Institute on Drug Abuse (NIDA)

Completed

Oral Nafamostat in Healthy Volunteers

Pharmacokinetics

United States
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

COVID-19

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

COVID-19

Russian Federation
Institut Pasteur de Dakar
Ministry of Health, Senegal; Fann Hospital, Senegal; Diamniadio Children Hospital... and other collaborators

Unknown

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)

COVID-19

Senegal
Kyungpook National University Hospital

Completed

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

Acute Kidney Injury
Yonsei University
SK Chemicals Co., Ltd.

Completed

The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy

Acute Kidney Injury

Korea, Republic of
Hansoh BioMedical R&D Company

Not yet recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
Harbin Medical University

Not yet recruiting

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer
Shen Lei

Not yet recruiting

Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI

Sepsis

China
Walton Centre NHS Foundation Trust
University of Liverpool; National Institute for Health Research, United Kingdom

Not yet recruiting

Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage (RESTARTtlCrH)

Traumatic Intracranial Haemorrhage
Talphera, Inc

Not yet recruiting

Nafamostat Efficacy in Phase 3 Registrational CRRT Study (NEPHRO)

Acute Kidney Injury
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Regina Elena Cancer Institute
University of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaborators

Recruiting

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer (Gisel)

Differentiated Thyroid Cancer | Gender

Italy
Xiaobo Yang, MD

Recruiting

Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Critical Illness | Anticoagulation

China
Elizabeth K. Lee MD
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Gynecologic Cancer | Ovarian Clear Cell Carcinoma

United States
Chong Kun Dang Pharmaceutical

Recruiting

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

COVID-19 Pneumonia

Korea, Republic of
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Recruiting

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients

Sepsis

China
University of Aarhus

Recruiting

The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)

Corona Virus Infection

Denmark, Sweden
Sunshine Lake Pharma Co., Ltd.

Recruiting

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Chronic HBV Infection

China
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Solid Tumors

United States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
University of Palermo

Completed

Rehabilitative Therapy and Pridinol in Patients With Lumbar Spondylarthrosis and Chronic Low Back Pain

Spondyloarthropathy

Italy
Ensysce Biosciences
National Institute on Drug Abuse (NIDA); Quotient Sciences

Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (MPAR-101)

Pharmacokinetics

United States
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Camostat With Bicalutamide for COVID-19 (COMBO)

Coronavirus Infection | Covid19 | SARS-CoV Infection

United States
Wonju Severance Christian Hospital

Enrolling by invitation

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study (Nafamostat)

Bleeding | Dialysis; Complications

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
First Affiliated Hospital of Zhejiang University

Enrolling by invitation

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Non Small Cell Lung Cancer

China
Opiant Pharmaceuticals Inc

Completed

Pharmacodynamic Evaluation of Intranasal Nalmefene

Pharmacodynamic

United States
Eisai Inc.

Completed

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Ewing Sarcoma | Rhabdomyosarcoma | Refractory or Recurrent Solid Tumors | Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Spain, United Kingdom, Italy, France, Germany, Greece, Poland, Switzerland
Stanford University

Completed

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)

Covid19

United States
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
Eisai Co., Ltd.

Completed

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Neoplasms | Carcinoma | Neoplasms, Glandular and Epithelial | Carcinoma, Hepatocellular

Japan
Heinrich-Heine University, Duesseldorf
The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit...

Completed

Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals (RES-Q-HR)

Corona Virus Infection | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 PCR Test Positive

Germany
Susanne Arnold

Terminated

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

COVID | Sars-CoV2

United States
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Instituto de Investigación Marqués de Valdecilla

Withdrawn

Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection

COVID 19 | Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
Instituto Nacional de Ciencias Medicas y Nutricion...

Terminated

Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

Hypertension | Obesity | Diabetes | Covid19

Mexico
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; University of Cambridge

Terminated

A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems (PRIME)

Drug-Related Side Effects and Adverse Reactions | Cardiovascular System Disease

United Kingdom
Eisai Inc.

Completed

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Alan Bryce

Unknown

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)

Severe Acute Respiratory Syndrome

United States

Search clinical trials for: Nafamostat mesilate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations